← Back to All US Stocks

PepGen Inc. (PEPG) Stock Fundamental Analysis & AI Rating 2026

PEPG Nasdaq Pharmaceutical Preparations DE CIK: 0001835597
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2025-12-31
SELL
72% Conf
Pending
Analysis scheduled

📊 PEPG Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-81.9M
Current Ratio: 11.94x
Debt/Equity: 0.00x
EPS: $-2.12
AI Rating: SELL with 72% confidence
PepGen Inc. (PEPG) receives a SELL rating with 72% confidence from our AI fundamental analysis based on SEC 10-K filings., and return on equity (ROE) of -60.8% Below is our complete PEPG stock analysis for 2026.

Is PepGen Inc. (PEPG) a Good Investment?

Claude

PepGen is a pre-revenue pharmaceutical company burning $81.6M annually with approximately 7-8 months of cash runway remaining, creating critical execution and funding risk. While the 25.6% YoY improvement in losses and strong balance sheet provide some mitigation, the company faces imminent capital requirements without demonstrated product commercialization.

Why Buy PepGen Inc. Stock? PEPG Key Strengths

Claude
  • + Strong balance sheet with $147.4M stockholders' equity and zero long-term debt
  • + Excellent liquidity position: $60.5M cash with 11.94x current ratio provides near-term stability
  • + Improving loss trend with 25.6% YoY EPS improvement indicates operational efficiency gains

PEPG Stock Risks: PepGen Inc. Investment Risks

Claude
  • ! Pre-revenue status with no commercial product generating income; dependency on single or limited pipeline assets
  • ! Critical cash runway of 7-8 months at current $81.6M annual burn rate; imminent dilution or failure risk without capital raise
  • ! Negative free cash flow of $81.9M with no clear path to profitability; high execution risk tied to clinical trial outcomes and regulatory approvals

Key Metrics to Watch

Claude
  • * Quarterly cash burn rate and remaining runway (watch for acceleration or deceleration)
  • * Clinical trial progress and FDA milestone achievements (critical for valuation inflection)
  • * Capital raise announcements or partnership deals (required for survival beyond Q3 2026)

PepGen Inc. (PEPG) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
$-89.7M
EPS (Diluted)
$-2.12
Free Cash Flow
$-81.9M
Total Assets
$173.9M
Cash Position
$60.5M

💡 AI Analyst Insight

Strong liquidity with a 11.94x current ratio provides a solid financial cushion.

PEPG Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -60.8%
ROA -51.6%
FCF Margin N/A

PEPG vs Healthcare Sector: How PepGen Inc. Compares

How PepGen Inc. compares to Healthcare sector averages

Net Margin
PEPG 0.0%
vs
Sector Avg 12.0%
PEPG Sector
ROE
PEPG -60.8%
vs
Sector Avg 15.0%
PEPG Sector
Current Ratio
PEPG 11.9x
vs
Sector Avg 2.0x
PEPG Sector
Debt/Equity
PEPG 0.0x
vs
Sector Avg 0.6x
PEPG Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is PepGen Inc. Stock Overvalued? PEPG Valuation Analysis 2026

Based on fundamental analysis, PepGen Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-60.8%
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

PepGen Inc. Balance Sheet: PEPG Debt, Cash & Liquidity

Current Ratio
11.94x
Quick Ratio
11.94x
Debt/Equity
0.00x
Debt/Assets
15.2%
Interest Coverage
N/A
Long-term Debt
N/A

PEPG Revenue & Earnings Growth: 5-Year Financial Trend

PEPG 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: PepGen Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.85 indicates the company is currently unprofitable.

PEPG Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

PepGen Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$81.6M
Cash generated from operations
Capital Expenditures
$264.0K
Investment in assets
Dividends
None
No dividend program

PEPG SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for PepGen Inc. (CIK: 0001835597)

📋 Recent SEC Filings

Date Form Document Action
Mar 30, 2026 8-K pepg-20260330.htm View →
Mar 6, 2026 4 xslF345X05/form4.xml View →
Mar 6, 2026 4 xslF345X05/form4.xml View →
Mar 6, 2026 4 xslF345X05/form4.xml View →
Mar 4, 2026 8-K pepg-20260304.htm View →

Frequently Asked Questions about PEPG

What is the AI rating for PEPG?

PepGen Inc. (PEPG) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PEPG's key strengths?

Claude: Strong balance sheet with $147.4M stockholders' equity and zero long-term debt. Excellent liquidity position: $60.5M cash with 11.94x current ratio provides near-term stability.

What are the risks of investing in PEPG?

Claude: Pre-revenue status with no commercial product generating income; dependency on single or limited pipeline assets. Critical cash runway of 7-8 months at current $81.6M annual burn rate; imminent dilution or failure risk without capital raise.

What is PEPG's revenue and growth?

PepGen Inc. reported revenue of N/A.

Does PEPG pay dividends?

PepGen Inc. does not currently pay dividends.

Where can I find PEPG SEC filings?

Official SEC filings for PepGen Inc. (CIK: 0001835597) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PEPG's EPS?

PepGen Inc. has a diluted EPS of $-2.12.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is PEPG a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, PepGen Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is PEPG stock overvalued or undervalued?

Valuation metrics for PEPG: ROE of -60.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy PEPG stock in 2026?

Our dual AI analysis gives PepGen Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PEPG's free cash flow?

PepGen Inc.'s operating cash flow is $-81.6M, with capital expenditures of $264.0K.

How does PEPG compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -60.8% (avg: 15%), current ratio 11.94 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2025-12-31 | Powered by Claude AI